|
|
|
|
|
|
|
By Rachel Grabenhofer, chief editor, Clinical Supply Leader
|
Early-stage biotechs often overbuild systems too soon. Alicia Collins, of Tune Therapeutics, explains why flexibility, simple processes, and realistic assumptions matter most.
|
|
|
|
|
|
|
|
By Laura Hay, Trax Group
|
Unused clinical trial supplies present complex logistical and compliance challenges. Learn why returns, reconciliation, and forecasting matter after a study ends.
|
|
|
|
|
|
|
|
By Hedley Rees and Angeliki Kotsianti, MD
|
When clinical supply reveals a constraint, someone must decide what it means for patients and data. Strong governance turns those signals into accountable action.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compliance, Costs, And Site Readiness In CAR-T Clinical Trials
|
|
By Sachit Verma, MD, MBA, FACHE, FAPCR
|
Navigate CAR-T trial complexity: uncover key compliance, budgeting, and site readiness strategies to ensure safe, efficient, and successful patient care.
|
|
|
|
|
|
Bridging Preclinical Science And Trial Supply Success
|
|
By Joseph G. Oberlander, Ph.D., PMP
|
Bridging preclinical science and clinical supply ensures therapies reach patients efficiently. Early planning, collaboration, and flexible supply chains prevent costly delays.
|
|
|
.png){kind=logo}
